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Background
Genetic analysis has been successful in identifying causative mutations for indi-
vidual cardiovascular risk factors. Success has been more limited in mapping sus-
ceptibility genes for clusters of cardiovascular risk traits, such as those in the meta-
bolic syndrome.
Methods
We identified three large families with coinheritance of early-onset coronary artery 
disease, central obesity, hypertension, and diabetes. We used linkage analysis and 
whole-exome sequencing to identify the disease-causing gene.
Results
A founder mutation was identified in DYRK1B, substituting cysteine for arginine at 
position 102 in the highly conserved kinase-like domain. The mutation precisely 
cosegregated with the clinical syndrome in all the affected family members and 
was absent in unaffected family members and unrelated controls. Functional char-
acterization of the disease gene revealed that nonmutant protein encoded by DYRK1B 
inhibits the SHH (sonic hedgehog) and Wnt signaling pathways and consequently 
enhances adipogenesis. Furthermore, DYRK1B promoted the expression of the key 
gluconeogenic enzyme glucose-6-phosphatase. The R102C allele showed gain-of-
function activities by potentiating these effects. A second mutation, substituting 
proline for histidine 90, was found to cosegregate with a similar clinical syndrome 
in an ethnically distinct family.
Conclusions
These findings indicate a role for DYRK1B in adipogenesis and glucose homeostasis 
and associate its altered function with an inherited form of the metabolic syndrome. 
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